Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
Janelle Mann, PharmD, BCOP
Advertisement
Articles by Janelle Mann, PharmD, BCOP
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
Advertisement
Latest Updated Articles
Considering Dosing and AE Management Strategies With Tarlatamab in SCLCPublished: March 24th 2025 | Updated:
- Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
Published: June 16th 2025 | Updated:
- Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Published: February 10th 2025 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Revumenib in R/R NPM1-Mutant AML
2
FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma
3
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
4
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
5
